Dorman Products (DORM) Misses Q2 EPS by 7c; Reaffirms FY23 Outlook

Dorman Products (NASDAQ: DORM) reported Q2 EPS of $1.01, $0.07 worse than the analyst estimate of $1.08. Revenue for the quarter came in at $480.6 million versus the consensus estimate of $497.16 million.

GUIDANCE:

Dorman Products sees FY2023 EPS of $5.15-$5.35, versus the consensus of $5.14. Dorman Products sees FY2023 revenue of $1.95-2 million, versus the consensus of $2 million.

For earnings history and earnings-related data on Dorman Products (DORM) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens on INBRX-106 Ph2 Results
• Can global equities keep rising? UBS sees these factors driving upside